Health
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer – EurekAlert
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung…
IMAGE: Tina Cascone, M.D., Ph.D.
view more
Credit: MD Anderson Cancer Center
HOUSTON — The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas…
-
General23 hours agoYoung boy flown to Brisbane hospital after K’gari dingo attack
-
General8 hours agoByford rail extension opening marks final stage of Perth Metronet
-
General20 hours agoBritish and US planes fly 12-hour mission to patrol Russian border
-
Noosa News24 hours agoWarm weather could make way for rain with ‘damaging winds, large hail’